PRISM Study-Pruritus Relief Through Itch Scratch Modulation

  • End date
    Dec 1, 2021
  • participants needed
  • sponsor
    Trevi Therapeutics
Updated on 17 January 2021
Clinical Ops Lead
Primary Contact
Study Site 128 (7.0 mi away) Contact
+77 other location


To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.


This is a randomized, double-blinded, placebo-controlled, 2-arm study with an open label extension period following double-blind treatment, to investigate the anti-pruritic efficacy and safety of Nalbuphine ER tablets. Subjects will be randomized to NAL ER (2-week titration followed by 162 mg twice daily [BID] for 12 weeks) or matching placebo (14 weeks duration), with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER total treatment duration 52 weeks including titration and subjects who received placebo will crossover to Nalbuphine ER Upon discontinuation of investigational product, all subjects will complete a 2-week off treatment Safety Follow-up Period, regardless of when and why the subject discontinued study treatment.

Treatment Matching Placebo Tablets, Nalbuphine ER Tablets
Clinical Study IdentifierNCT03497975
SponsorTrevi Therapeutics
Last Modified on17 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Prurigo Nodularis?
Do you have any of these conditions: Do you have Prurigo Nodularis??
Do you have any of these conditions: Do you have Prurigo Nodularis??
Individuals diagnosed with generalized nodular PN, covering 2 separate body parts, and 10 or more pruriginous nodules
Severe itch due to PN
Age 18 years and older at the time of consent, and a life expectancy of at least 18 months

Exclusion Criteria

Pruritus due to localized PN (only one body part affected), or less than 10 nodules
Pruritic dermatoses other than PN that were active/in need of treatment in the last 6 months, such as atopic dermatitis, bullous pemphigoid or other dermatologic conditions that in the opinion of the Investigator could confound the ability to assess PN related itch
Unresolved acute secondary dermatoses active (unresolved) in the last (a) 4 weeks: localized contact dermatitis, environmental exposures, superficial burns, or viral exanthems; (b) 8 weeks: skin or environmental infestations, such as scabies, lice, or bed bugs
Other non-dermatologic disease that could be a potential cause of concomitant pruritus (e.g., thyroid disease, celiac disease, hepatitis C virus [HCV]) must either have resolved, been successfully treated (i.e., HCV RNA negative) or must be successfully managed with stable, optimized treatment (e.g., thyroid replacement, dietary management with resolution of symptoms, respectively) for at least 3 months prior to screening
History of a major psychiatric disorder such as bipolar disorder or schizophrenia. History of substance abuse in the last 3 years. Individuals using sedating antidepressants. Individuals using non-sedating antidepressants must be on a stable dose for a minimum of 8 weeks prior to entering the study
Known intolerance (GI, CNS symptoms) or hypersensitivity/drug allergy to opioids
Use of certain concomitant medications and treatments within a period prior to the study, or requirement for these medications during the study
Within 14 days prior to screening: opiates, gabapentin, pregabalin, calcineurin inhibitors, cannabinoid agonists, capsaicin, cryosurgery, topical doxepin, thalidomide or methotrexate, antihistamines (systemic or topical), and topical corticosteroids, cryotherapy
Within 4 weeks prior to screening: ultraviolet (UV)-therapy, exposure to any investigational medication, including placebo
Within 3 months prior to screening: Non-insulin biologics (including monoclonal antibodies) that modify the immune system
Individuals taking monoamine oxidase inhibitors are excluded, as concomitant opiate use may increase the risk for serotonin syndrome
Individuals who have previously received dupilumab or nemolizumab are excluded
Myocardial infarction or acute coronary syndrome within the previous 3 months, as reported by the subject
Individuals with prolonged QTcF
Individuals with HIV can be included if they meet the following criteria: (a)
currently on a stable (> 6 months stable use) and well tolerated highly active
antiretroviral therapy regimen; (b) CD4 count > 500 cells/mL; and (c) HIV
ribonucleic acid (RNA) < 50 copies/mL documented for at least 6 months prior
to enrollment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet